Moreover, our findings suggested that exposure to mipomersen directed at APOB might elevate VTE risk, including DVT and PE, Ibrolipim targeting LPL might increase the risk of VTE and PE, and Volanesorsen targeting APOC3 also showed a similar phenomenon in DVT, but these points have not yet been confirmed. This evidence concerns the gene LPL and deep vein thrombosis.